CY12-RP2 resulted in a 60.6% reduction in tumor growth in immunocompetent murine models and reversed immune evasion by attenuating PDPN-dependent, β-catenin-mediated upregulation of PD-L1. The gene discussed is PDPN; the disease is neoplasm.